Novartis Wins FDA Approval For Fabhalta In IgA Nephropathy

Source Summary

Novartis AG (NVS) announced that the U.S. FDA has granted traditional approval for Fabhalta (iptacopan), making it the first and only complement inhibitor shown to significantly slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression.